CXCR4 and neoplasm: Treatment of OSCC tumor bearing mice with the CXCR4 inhibitor AMD3100 revealed that CXCR4 inhibition induced tumor necrosis by suppressing intratumoral angiogenesis, suggesting the potential for molecular therapy targeting CXCR4-positive tumor blood vessels [16].